Meeting
2019 ASCO Annual Meeting
Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.
Authors
Paul K. Paik
Memorial Sloan Kettering Cancer Center, New York, NY
Paul K. Paik , Linda Su Hyun Ahn , Michelle S. Ginsberg , Andrew J. Plodkowski , Rachel Kim , L. Austin Doyle , Charles M. Rudin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02417701
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9085)
DOI
10.1200/JCO.2019.37.15_suppl.9085
Abstract #
9085
Poster Bd #
408
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.
First Author: Paul K. Paik
Poster
2018 ASCO Annual Meeting
Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.
First Author: Paul K. Paik
Poster
2023 ASCO Annual Meeting
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
First Author: Sukhmani Kaur Padda
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely